Uso da Cannabis medicinal e autismo
DOI:
https://doi.org/10.37085/jmmv2.n1.2020.pp.5-14Palavras-chave:
Transtorno do Espectro Autista, CBD, RevisãoResumo
O Transtorno do Espectro Autista (TEA) é caracterizado por déficits persistentes na comunicação social, padrões restritos e repetitivos de comportamento, interesses ou atividades e, muitas vezes, deficiências intelectuais. O TEA possui várias comorbidades prevalentes, como distúrbios do sono, distúrbio do déficit de atenção/hiperatividade e epilepsia. Existe um interesse crescente em canabinóides, especialmente canabidiol (CBD), como monoterapia ou tratamento complementar para os principais sintomas e comorbidades do TEA. No entanto, a ação neural do CBD, sua relevância e eficácia para o TEA, ainda permanece em discussão. O objetivo deste trabalho foi empreender uma revisão de literatura sobre estudos que tratem dos efeitos do uso de Cannabis sativa (cannabis). no indivíduo com TEA. Foram encontrados 45 estudos nas bases de dados PubMed, MEDLINE e LILACS , dos quais, apenas 5 conformaram-se com os critérios de aceitação, com os descritores: Cannabis AND Autism Spectrum Disorder. Observamos que são necessários estudos adicionais para examinar os prós e contras do CBD e outros canabinóides no TEA, antes que eles sejam estabelecidos como tratamento para sintomas e comorbidades do TEA. Nenhum dos trabalhos apresentam dados clínicos ou pré-clínicos convincentes que demonstrem a eficácia e segurança da cannabis medicinal, incluindo o CBD.
Downloads
Referências
Ramaswami G, Geschwind DH (2018) Genetics of autism spectrum disorder, 1st ed, Handbook of Clinical Neurology. Disponível em: https://doi.org/10.1016/B978-0-444-63233-3.00021-X.
Soke GN, Rosenberg SA, Hamman RF, et al. (2016) Brief report: prevalence of selfinjurious behaviors among children with autism spectrum disorder -a population-based study. J Autism Dev Disord. 46(11):3607–3614. Disponível em: https://doi.org/10.1007/s10803-016-2879-1.
Bozzi Y, Provenzano G, Casarosa S (2018) Neurobiological bases of autism–epilepsy comorbidity: a focus on excitation/inhibition imbalance. Eur J Neurosci. 47:534-548. Disponível em: https://doi.org/10.1111/ejn.13595.
Griffiths KK, Levy RJ (2017) Evidence of Mitochondrial Dysfunction in Autism: Biochemical Links, Genetic-Based Associations, and Non-Energy-Related Mechanisms. Oxid Med Cell Longev 20174314025. Disponível em: https://doi.org/10.1155/2017/4314025.
Fung LK, Mahajan R, Nozzolillo A et al. (2016) Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis. Pediatrics 137(s2):e20152851K. Disponível em: https://doi.org/10.1542/peds.2015-2851K.
Sahoo S, Padhy SK, Singla N, Singh A (2017) Effectiveness of clozapine for the treatment of psychosis and disruptive behaviour in a child with Atypical Autism: A case report and a brief review of the evidence. Asian J Psychiatr 29:194-195. Disponível em: https://doi.org/10.1016/j.ajp.2017.07.012.
Hirota T, Veenstra-Vanderweele J, Hollander E, Kishi T (2014) Antiepileptic medications in autism spectrum disorder: a systematic review and meta-analysis. J Autism Dev Disord 44(4):948-957. Disponível em: https://doi.org/10.1007/s10803-013-1952-2.
Hesami O, Hosseini SS, Kazemi N, Hosseini-Zijoud SM, Moghaddam NB, Assarzadegan F, et al. (2016) Evaluation of ocular side effects in the patients on topiramate therapy for control of migrainous headache. J Clin Diagn Res. 10(3): NC01–4. Disponível em: https://doi.org/10.7860/jcdr/2016/16263.7339.
Garstang J, Wallis M. (2006) Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 32(5):585-589. Disponível em: https://doi.org/10.1111/j.1365-2214.2006.00616.x.
Ghaziuddin M, Zafar S (2008) Psychiatric comorbidity of adults with autism spectrum disorders. Clinical Neuropsychiatry 5(1):9-12. Disponível em:https://www.researchgate.net/publication/288295415_Psychiatric_comorbidity_of_adults_with_autism_spectrum_disorders.
Stepanova E, Dowling S, Phelps M, Findling, R. L (2017) Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents. Dialogues Clin. Neurosci 19(4):395–402. Disponível em: PMID: 29398934.
Zamberletti E, Gabaglio M, Parolaro D. (2017) The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models. Int. J. Mol. Sci. 18(9): 1916. Disponível em: https://doi.org/10.3390/ijms18091916.
Behere AP, Behere PB, Sathyanarayana Rao TS. (2017) Cannabis: Does it have a medicinal value? Indian J. Psychiatry 59(3): 262–263. Disponível em: https://doi.org/10.4103/psychiatry.IndianJPsychiatry_208_17.
Brenneisen R (2007) Chemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents, in: Marijuana and the Cannabinoids. Humana Press, Totowa, NJ, pp.17–49. Disponível em: https://doi.org/10.1007/978-1-59259-947-9_2.
Gu B (2017) Cannabidiol provides viable treatment opportunity for multi pleneurological pathologies of autism spectrum disorder. Glob. Drugs Ther 2(6):1-4. Disponível em: https://doi.org/10.15761/GDT.1000134.
Gallily R, Yekhtin, Z, Hanuš, LO. (2015) Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol. Pharmacol. Pharm 6(02):75. Disponível em: https://doi.org/10.4236/pp.2015.62010.
Rong C, Lee Y, Carmona NE, et al. (2017) Cannabidiol in medical marijuana: Research vistas and potential opportunities. Pharmacol Res 121, 213–218. Disponível em: https://doi.org/10.1016/j.phrs.2017.05.005.
Russo, EB. (2017) Cannabidiol Claims and Misconceptions. Trends Pharmacol. Sci. 38: 198–201. Disponível em: https://doi.org/10.1016/j.tips.2016.12.004.
Cheng D, Low JK, Logge W, et al. (2014) Chronic cannabidiol treatment improves social and object recognition in double transgenic APP swe / PS1 Δ E9 mice. Psychopharmacology 231(15):3009-3017. Disponível em: https://doi.org/10.1007/s00213-014-3478-5.
Devinsky O, Cilio MR, Cross H, et al. (2014) Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55(6):791–802. Disponível em: https://doi.org/10.1111/epi.12631.
Iuvone T, Esposito G, Esposito R, et al. (2004) Neuroprotective effect of cannabidiol, a non‐psychoactive component from Cannabis sativa, on β‐amyloid‐induced toxicity in PC12 cells. J. Neurochem 89(1):134–141. Disponível em: https://doi.org/10.1111/j.1471-4159.2003.02327.x.
Khalil RB (2012) Would some cannabinoids ameliorate symptoms of autism? Eur. Child Adolesc. Psychiatry 21(4):237–238. Disponível em: https://doi.org/10.1007/s00787-012-0255-z.
Qin N, Neeper MP, Liu Y, Hutchinson TL, Lubin ML, Flores CM (2008) TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 28(24):6231–6238. Disponível em: https://doi.org/10.1523/JNEUROSCI.0504-08.2008
Bisogno T, Hanuš L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology 134(4):845-852. Disponível em: https://doi.org/10.1038/sj.bjp.0704327.
Linge R, Jiménez-Sánchez L, Campa L, et al. (2016) Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: Role of 5-HT1Areceptors. Neuropharmacology 103:16-26. Disponível em: https://doi.org/10.1016/j.neuropharm.2015.12.017.
Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT-1a receptors. Neurochem Res 30(8):1037–1043. Disponível em: https://doi.org/10.1007/s11064-005-6978-1
Howlett AC, Blume LC, Dalton GD (2010) CB 1 Cannabinoid Receptors and their Associated Proteins. Curr. Med. Chem 17(14):1382-1393. Disponível em: https://doi.org/10.2174/092986710790980023.
Karhson DS, Krasinska KM, Dallaire JA et al. (2018) Plasma anandamide concentrations are lower in children with autism spectrum disorder. Mol. Autism 9(1):18. Disponível em: https://doi.org/10.1186/s13229-018-0203-y.
Pacher P, Mechoulam R (2011) Is lipidsignaling through cannabinoid 2 receptors part of a protective system? Prog. Lipid Res 50(2):193–211. Disponível em: https://doi.org/10.1016/j.plipres.2011.01.001.
Wei D, Lee D, Cox CD, et al. (2015) Endocannabinoid signaling mediates oxytocin-driven social reward. Proc. Natl. Acad. Sci. 112(45):14084–14089. Disponível em: https://doi.org/10.1073/pnas.1509795112.
Autism spectrum disorders. WHO (World Health Organization). Enero 2016. Acesso em: 10 de Dez 2019. Disponível em: https://www.who.int/news-room/fact-sheets/detail/autism-spectrum-disorders.
Dow-Edwards D (2018) Maternal Drug Abuse and Adverse Effects on Neurobehavior of Offspring. In Handbook of Developmental Neurotoxicology 487-497. Academic Press. Disponível em: https://doi.org/10.1016/B978-0-12-809405-1.00043-2.
Rubino T, Parolaro D (2016) The impact of exposure to cannabinoids in adolescence: insights from animal models. Biol. Psychiatry 79(7):578-585. Disponível em: https://doi.org/10.1016/j.biopsych.2015.07.024.
Bellis MD, De Keshavan MS, Beers SR, et al (2001) Sex Differences in Brain Maturation during Childhood and Adolescence. Cereb. Cortex 11(6):552-557. Disponível em: https://doi.org/https://doi.org/10.1093/cercor/11.6.552.
Chambers RA, Taylor JR, Potenza MN (2003) Developmental neurocircuitry of motivation in
adolescence: a critical period of addiction vulnerability. Am J Psychiatry 160(6): 1041–1052. Disponível em: https://doi.org/10.1176/appi.ajp.160.6.1041.
Schneider M (2008) Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict. Biol 13(2): 253-263. Disponível em: https://doi.org/10.1111/j.1369-1600.2008.00110.x.
Spear LP (2000) The adolescent brain and age-related behavioral manifestations. Neurosci. Biobehav. Ver 24:417–463. Disponível em: https://doi.org/10.1016/S0149-7634(00)00014-2.
Chadwick B, Miller ML, Hurd YL (2013) Cannabis use during adolescent development: susceptibility to psychiatric illness. Front. Psycho 4:129. Disponível em: https://doi.org/10.3389/fpsyt.2013.00129.
Scuderi C, Filippis DDe, Iuvone T, et al (2009) Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res. 23(5): 597–602. Disponível em: https://doi.org/10.1002/ptr.2625.
Dryburgh LM, Bolan NS, Grof CP, et al. (2018) Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects. Br J Clin Pharmacol 84(11):2468-2476. Disponível em: https://doi.org/10.1111/bcp.13695.
Carvalho RK, Santos ML, Souza MR, et al. (2018) Chronic exposure to cannabidiol induces reproductive toxicity in male Swiss mice. J Appl Toxicol 38(9):1215-1223. Disponível em: https://doi.org/10.1002/jat.3631.
Shannon S, Opila-Lehman J (2016) Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. Perm J 20(4):108. Disponível em: https://doi.org/10.7812/TPP/16-005.
Aran A, Cassuto H, Lubotzky A (2018) Cannabidiol based medical cannabis in children with autism-a retrospective feasibility study (P3. 318). Disponível em: https://doi.org/10.1177/136236131452464.
Poleg S, Golubchik P, Offen D, Weizman, A. (2019) Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. Prog Neuropsychopharmacol Biol Psychiatry 89: 90-96. Disponível em: https://doi.org/10.1016/j.pnpbp.2018.08.030
Reece AS, Hulse GK. (2019) Impacts of cannabinoid epigenetics on human development: reflections on Murphy et. al.‘cannabinoid exposure and altered DNA methylation in rat and human sperm’epigenetics. Epigenetics 14(11):1208-1221. Disponível em: https://doi.org/10.1080/15592294.2019.1633868
Pretzsch CM, Voinescu B, Mendez MA, et al. (2019) The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). J. Psychopharmacol 1-8. Disponível em: https://doi.org/10.1177/0269881119858306
Pretzsch CM, Freyberg J, Voinescu B, Lythgoe D, Horder J,et al. (2019) Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology 44(8):1398–1405. Disponível em: https://doi.org/10.1038/s41386-019-0333-8
Wei D, Dinh D, Lee D, et al. (2016). Enhancement of anandamide-mediated endocannabinoid signaling corrects autism-related social impairment. Cannabis and cannabinoid research 1(1):81-89. Disponível em: https://dx.doi.org/10.1089%2Fcan.2015.0008
Campos AC, Fogaca MV, Scarante FF, Joca, et al. (2017) Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders. Front Pharmacol 8:269. Disponível em: https://doi.org/10.3389/fphar.2017.00269.
Radesky JS, Schumacher J, Zuckerman B (2015) Mobile and interactive media use by young children: the good, the bad, and the unknown. Pediatrics 135(1):1–3. Disponível em: https://doi.org/10.1542/peds.2014-2251.
Downloads
Publicado
Como Citar
Licença
Os direitos autorais para artigos publicados no Jornal Memorial da Medicina são do autor, com direitos de primeira publicação para a revista. Em virtude de aparecerem nesta revista de acesso público, os artigos são de uso gratuito, com atribuições próprias, em aplicações educacionais e não comerciais. O Jornal Memorial da Medcina permitirá o uso dos trabalhos publicados para fins não comerciais, incluindo direito de enviar o trabalho para bases de dados de acesso público. Os artigos publicados são de total e exclusiva responsabilidade dos autores. Há encargos para submissão no processamento de artigos (Articles Processing Charge - APC).
